PEG-rhG-CSF治疗乳腺癌化疗后白细胞减少症的有效性及安全性研究  

Efficacy and safety study of PEG-rhG-CSF in the treatment of post-chemotherapy leukopenia in breast cancer

作　　者：刘琨 杨成轩 LIU Kun;YANG Chengxuan(Department of Pharmacy,the First People’s Hospital of Xinxiang City,Xinxiang 453099,China;Department of Mammography,the First People’s Hospital of Xinxiang City,Xinxiang 453099,China)

机构地区：[1]新乡市第一人民医院药学部,河南新乡453099 [2]新乡市第一人民医院乳腺科,河南新乡453099

出　　处：《上海医药》2023年第11期44-47,共4页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:分析聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)治疗乳腺癌化疗后白细胞减少症的有效性和安全性。方法:回顾性分析80例接受化疗的乳腺癌患者,将他们分为对照组[n=40,采用重组人粒细胞刺激因子(rhG-CSF)治疗]和观察组(n=40,采用PEG-rhG-CSF治疗),比较两组白细胞计数(WBC)、绝对中性粒细胞计数(ANC)和其动态变化情况、药物费用及不良反应发生情况。结果:观察组治疗后3 d的WBC和治疗21 d内的ANC和药物费用均高于对照组(P<0.05);两组不良反应发生情况比较差异无统计学意义(P>0.05)。结论:PEG-rhG-CSF可提高乳腺癌化疗后白细胞减少症治疗的有效性,安全性尚可。Objective:To analyze the efficacy and safety of pegylated recombinant human granulocyte-colony stimulating factor(PEG-rhG-CSF)in the treatment of post-chemotherapy leukopenia in breast cancer.Methods:The data from 80 breast cancer patients treated with chemotherapy were retrospectively analyzed and they were divided into a control group[n=40,treated with recombinant human granulocyte-colony stimulating factor(rhG-CSF)]and an observation group(n=40,treated with PEG-rhG-CSF).The white blood cell count(WBC),absolute neutrophil count(ANC)and their dynamic changes,drug costs and the incidence of adverse reactions were compared between the two groups.Results:The WBC at 3 d after treatment and ANC within 21 d of treatment and drug cost were all higher in the observation group than in the control group(P<0.05).There were no statistically significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:PEGrhG-CSF can improve the treatment effectiveness of leukopenia occurred after chemotherapy for breast cancer and the safety is acceptable.

关 键 词：聚乙二醇化重组人粒细胞刺激因子 乳腺癌 化疗 白细胞减少症 

分 类 号：R937.4[医药卫生—生药学] R737.9[医药卫生—药学]